After-Hours Movers: GBT Gains on Takeover Chatter, Lucid Falls Following Results

StreetInsider2022-08-03

After-Hours Stock Movers:

Global Blood Therapeutics (NASDAQ: GBT) 30% HIGHER; said to draw takeover interest - Bloomberg

Yellow Corporation (NASDAQ: YELL) 27% HIGHER; reported Q2 EPS of $1.17, $0.72 better than the analyst estimate of $0.45. Revenue for the quarter came in at $1.42 billion versus the consensus estimate of $1.4 billion.

Lucid Group (NASDAQ: LCID) 12% LOWER; reported Q2 EPS of ($0.33), $0.06 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $97.3 million versus the consensus estimate of $145.49 million.

MercadoLibre (NASDAQ: MELI) 12% HIGHER; reported Q2 EPS of $2.43, $0.50 better than the analyst estimate of $1.93. Revenue for the quarter came in at $2.6 billion versus the consensus estimate of $2.51 billion.

Skillz (NYSE: SKLZ) 12% LOWER; reported Q2 EPS of ($0.15), in-line with the analyst estimate of ($0.15). Revenue for the quarter came in at $93 million versus the consensus estimate of $92.8 million. Skillz sees FY2022 EPS of $275.00, versus the consensus of $399.13.

Medifast (NYSE: MED) 11% LOWER; reported Q2 EPS of $3.87, $0.64 better than the analyst estimate of $3.23. Revenue for the quarter came in at $453.3 million versus the consensus estimate of $447.87 million. Medifast sees FY2022 EPS of $12.70-$14.10, versus the consensus of $15.38. Medifast sees FY2022 revenue of $1.58-1.66 billion, versus the consensus of $1.8 billion.

Fortinet (NASDAQ: FTNT) 9% LOWER; reported Q2 EPS of $0.24, $0.02 better than the analyst estimate of $0.22. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $1.03 billion. Fortinet sees Q3 2022 EPS of $0.26-$0.28, versus the consensus of $0.27. Fortinet sees Q3 2022 revenue of $1.105-1.135 billion, versus the consensus of $1.12 billion. Fortinet sees FY2022 EPS of $1.01-$1.06, versus the consensus of $1.03. Fortinet sees FY2022 revenue of $4.35-4.4 billion, versus the consensus of $4.38 billion.

PacBio (NASDAQ: PACB) 8% LOWER; Q2 Revenue of $35.5 million, a 16% increase compared with $30.6 million in the prior year period.

Clorox (NYSE: CLX) 6% LOWER; reported Q4 EPS of $0.93, in-line with the analyst estimate of $0.93. Revenue for the quarter came in at $1.8 billion versus the consensus estimate of $1.86 billion. Clorox sees FY2023 EPS of $3.82-$4.22, versus the consensus of $5.26.

Lumen Technologies (NYSE: LUMN) 6% LOWER; reported Q2 EPS of $0.35, $0.11 worse than the analyst estimate of $0.46. Revenue for the quarter came in at $4.61 billion versus the consensus estimate of $4.58 billion. The company reiterated its full-year 2022 financial outlook

Albemarle (NYSE: ALB) 5% HIGHER; reported Q2 EPS of $3.45, $0.45 better than the analyst estimate of $3.00. Revenue for the quarter came in at $1.48 billion versus the consensus estimate of $1.43 billion. Albemarle sees FY2022 EPS of $19.25-$22.25, versus the consensus of $15.87. Albemarle sees FY2022 revenue of $7.1-7.5 billion, versus the consensus of $6.89 billion.

Sunrun (NASDAQ: RUN) 5% HIGHER; reported Q2 EPS of ($0.06), $0.07 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $584.6 million versus the consensus estimate of $501.53 million.

Qorvo (NASDAQ: QRVO) 4% LOWER; reported Q1 EPS of $2.25, $0.14 better than the analyst estimate of $2.11. Revenue for the quarter came in at $1.04 billion versus the consensus estimate of $1.02 billion. Qorvo sees Q2 2023 EPS of $2.45-$2.65, versus the consensus of $2.64. Qorvo sees Q2 2023 revenue of $1.12-1.15 billion, versus the consensus of $1.14 billion.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

来人
2022-08-04
来人
Done
74rk
2022-08-04
74rk
9
小虎一飞冲天
2022-08-04
小虎一飞冲天
Like pls
Looyusooi
2022-08-04
Looyusooi
Ok
Geoz88
2022-08-04
Geoz88
Yes
- 小虎一飞冲天:
  👍🏼
T202311701
2022-08-04
T202311701
Ooo
- 74rk:
  ok

Leave a comment

303

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2256914424?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2022-08-04 07:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2256914424","market":"us","top_or_hot":-1,"title":"After-Hours Movers: GBT Gains on Takeover Chatter, Lucid Falls Following Results","media":"StreetInsider","content":"<html><head></head><body><p><img src=\"https://static.tigerbbs.com/9609a375d55501d49f219b3fd7adbb75\" tg-width=\"200\" tg-height=\"134\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p><b>After-Hours Stock Movers:</b></p><p>Global Blood Therapeutics (NASDAQ: GBT) 30% HIGHER; said to draw takeover interest - Bloomberg</p><p><a href=\"https://laohu8.com/S/YELL\">Yellow Corporation</a> (NASDAQ: YELL) 27% HIGHER; reported Q2 EPS of $1.17, $0.72 better than the analyst estimate of $0.45. Revenue for the quarter came in at $1.42 billion versus the consensus estimate of $1.4 billion.</p><p>Lucid Group (NASDAQ: LCID) 12% LOWER; reported Q2 EPS of ($0.33), $0.06 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $97.3 million versus the consensus estimate of $145.49 million.</p><p><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> (NASDAQ: MELI) 12% HIGHER; reported Q2 EPS of $2.43, $0.50 better than the analyst estimate of $1.93. Revenue for the quarter came in at $2.6 billion versus the consensus estimate of $2.51 billion.</p><p>Skillz (NYSE: SKLZ) 12% LOWER; reported Q2 EPS of ($0.15), in-line with the analyst estimate of ($0.15). Revenue for the quarter came in at $93 million versus the consensus estimate of $92.8 million. Skillz sees FY2022 EPS of $275.00, versus the consensus of $399.13.</p><p>Medifast (NYSE: MED) 11% LOWER; reported Q2 EPS of $3.87, $0.64 better than the analyst estimate of $3.23. Revenue for the quarter came in at $453.3 million versus the consensus estimate of $447.87 million. Medifast sees FY2022 EPS of $12.70-$14.10, versus the consensus of $15.38. Medifast sees FY2022 revenue of $1.58-1.66 billion, versus the consensus of $1.8 billion.</p><p>Fortinet (NASDAQ: FTNT) 9% LOWER; reported Q2 EPS of $0.24, $0.02 better than the analyst estimate of $0.22. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $1.03 billion. Fortinet sees Q3 2022 EPS of $0.26-$0.28, versus the consensus of $0.27. Fortinet sees Q3 2022 revenue of $1.105-1.135 billion, versus the consensus of $1.12 billion. Fortinet sees FY2022 EPS of $1.01-$1.06, versus the consensus of $1.03. Fortinet sees FY2022 revenue of $4.35-4.4 billion, versus the consensus of $4.38 billion.</p><p>PacBio (NASDAQ: PACB) 8% LOWER; Q2 Revenue of $35.5 million, a 16% increase compared with $30.6 million in the prior year period.</p><p>Clorox (NYSE: CLX) 6% LOWER; reported Q4 EPS of $0.93, in-line with the analyst estimate of $0.93. Revenue for the quarter came in at $1.8 billion versus the consensus estimate of $1.86 billion. Clorox sees FY2023 EPS of $3.82-$4.22, versus the consensus of $5.26.</p><p><a href=\"https://laohu8.com/S/LUMN\">Lumen Technologies</a> (NYSE: LUMN) 6% LOWER; reported Q2 EPS of $0.35, $0.11 worse than the analyst estimate of $0.46. Revenue for the quarter came in at $4.61 billion versus the consensus estimate of $4.58 billion. The company reiterated its full-year 2022 financial outlook</p><p>Albemarle (NYSE: ALB) 5% HIGHER; reported Q2 EPS of $3.45, $0.45 better than the analyst estimate of $3.00. Revenue for the quarter came in at $1.48 billion versus the consensus estimate of $1.43 billion. Albemarle sees FY2022 EPS of $19.25-$22.25, versus the consensus of $15.87. Albemarle sees FY2022 revenue of $7.1-7.5 billion, versus the consensus of $6.89 billion.</p><p>Sunrun (NASDAQ: RUN) 5% HIGHER; reported Q2 EPS of ($0.06), $0.07 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $584.6 million versus the consensus estimate of $501.53 million.</p><p>Qorvo (NASDAQ: QRVO) 4% LOWER; reported Q1 EPS of $2.25, $0.14 better than the analyst estimate of $2.11. Revenue for the quarter came in at $1.04 billion versus the consensus estimate of $1.02 billion. Qorvo sees Q2 2023 EPS of $2.45-$2.65, versus the consensus of $2.64. Qorvo sees Q2 2023 revenue of $1.12-1.15 billion, versus the consensus of $1.14 billion.</p></body></html>","source":"highlight_streetinsider","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Movers: GBT Gains on Takeover Chatter, Lucid Falls Following Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Movers: GBT Gains on Takeover Chatter, Lucid Falls Following Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-04 07:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=20412907><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Global Blood Therapeutics (NASDAQ: GBT) 30% HIGHER; said to draw takeover interest - BloombergYellow Corporation (NASDAQ: YELL) 27% HIGHER; reported Q2 EPS of $1.17, $0.72 ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=20412907\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.streetinsider.com/dr/news.php?id=20412907","article_id":"2256914424","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2256914424","pubTimestamp":1659569267,"columns":[],"sourceInfo":{"source_id":"highlight_streetinsider","name":"StreetInsider"},"weMediaInfo":null,"summary":"After-Hours Stock Movers:Global Blood Therapeutics (NASDAQ: GBT) 30% HIGHER; said to draw takeover i","collect":0,"end_time":0,"defaultTopTitle":"streetinsider.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"下班后的推动者：GBT在收购传言中获利，Lucid在结果后下跌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GBT":1,"LCID":1},"content_text":"After-Hours Stock Movers:Global Blood Therapeutics (NASDAQ: GBT) 30% HIGHER; said to draw takeover interest - BloombergYellow Corporation (NASDAQ: YELL) 27% HIGHER; reported Q2 EPS of $1.17, $0.72 better than the analyst estimate of $0.45. Revenue for the quarter came in at $1.42 billion versus the consensus estimate of $1.4 billion.Lucid Group (NASDAQ: LCID) 12% LOWER; reported Q2 EPS of ($0.33), $0.06 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $97.3 million versus the consensus estimate of $145.49 million.MercadoLibre (NASDAQ: MELI) 12% HIGHER; reported Q2 EPS of $2.43, $0.50 better than the analyst estimate of $1.93. Revenue for the quarter came in at $2.6 billion versus the consensus estimate of $2.51 billion.Skillz (NYSE: SKLZ) 12% LOWER; reported Q2 EPS of ($0.15), in-line with the analyst estimate of ($0.15). Revenue for the quarter came in at $93 million versus the consensus estimate of $92.8 million. Skillz sees FY2022 EPS of $275.00, versus the consensus of $399.13.Medifast (NYSE: MED) 11% LOWER; reported Q2 EPS of $3.87, $0.64 better than the analyst estimate of $3.23. Revenue for the quarter came in at $453.3 million versus the consensus estimate of $447.87 million. Medifast sees FY2022 EPS of $12.70-$14.10, versus the consensus of $15.38. Medifast sees FY2022 revenue of $1.58-1.66 billion, versus the consensus of $1.8 billion.Fortinet (NASDAQ: FTNT) 9% LOWER; reported Q2 EPS of $0.24, $0.02 better than the analyst estimate of $0.22. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $1.03 billion. Fortinet sees Q3 2022 EPS of $0.26-$0.28, versus the consensus of $0.27. Fortinet sees Q3 2022 revenue of $1.105-1.135 billion, versus the consensus of $1.12 billion. Fortinet sees FY2022 EPS of $1.01-$1.06, versus the consensus of $1.03. Fortinet sees FY2022 revenue of $4.35-4.4 billion, versus the consensus of $4.38 billion.PacBio (NASDAQ: PACB) 8% LOWER; Q2 Revenue of $35.5 million, a 16% increase compared with $30.6 million in the prior year period.Clorox (NYSE: CLX) 6% LOWER; reported Q4 EPS of $0.93, in-line with the analyst estimate of $0.93. Revenue for the quarter came in at $1.8 billion versus the consensus estimate of $1.86 billion. Clorox sees FY2023 EPS of $3.82-$4.22, versus the consensus of $5.26.Lumen Technologies (NYSE: LUMN) 6% LOWER; reported Q2 EPS of $0.35, $0.11 worse than the analyst estimate of $0.46. Revenue for the quarter came in at $4.61 billion versus the consensus estimate of $4.58 billion. The company reiterated its full-year 2022 financial outlookAlbemarle (NYSE: ALB) 5% HIGHER; reported Q2 EPS of $3.45, $0.45 better than the analyst estimate of $3.00. Revenue for the quarter came in at $1.48 billion versus the consensus estimate of $1.43 billion. Albemarle sees FY2022 EPS of $19.25-$22.25, versus the consensus of $15.87. Albemarle sees FY2022 revenue of $7.1-7.5 billion, versus the consensus of $6.89 billion.Sunrun (NASDAQ: RUN) 5% HIGHER; reported Q2 EPS of ($0.06), $0.07 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $584.6 million versus the consensus estimate of $501.53 million.Qorvo (NASDAQ: QRVO) 4% LOWER; reported Q1 EPS of $2.25, $0.14 better than the analyst estimate of $2.11. Revenue for the quarter came in at $1.04 billion versus the consensus estimate of $1.02 billion. Qorvo sees Q2 2023 EPS of $2.45-$2.65, versus the consensus of $2.64. Qorvo sees Q2 2023 revenue of $1.12-1.15 billion, versus the consensus of $1.14 billion.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9906704589,"gmtCreate":1659585204444,"gmtModify":1705981935670,"author":{"id":"3575544575320394","authorId":"3575544575320394","name":"来人","avatar":"https://static.tigerbbs.com/0af89587decbb8a1d3e1596adc29cb98","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3575544575320394","authorIdStr":"3575544575320394"},"htmlText":"Done","listText":"Done","text":"Done","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9906704589","repostId":2256914424,"repostType":4,"repost":{"id":"2256914424","kind":"highlight","pubTimestamp":1659569267,"share":"https://ttm.financial/m/news/2256914424?lang=&edition=full_marsco","pubTime":"2022-08-04 07:27","market":"us","language":"en","title":"After-Hours Movers: GBT Gains on Takeover Chatter, Lucid Falls Following Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2256914424","media":"StreetInsider","summary":"After-Hours Stock Movers:Global Blood Therapeutics (NASDAQ: GBT) 30% HIGHER; said to draw takeover i","content":"<html><head></head><body><p><img src=\"https://static.tigerbbs.com/9609a375d55501d49f219b3fd7adbb75\" tg-width=\"200\" tg-height=\"134\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p><b>After-Hours Stock Movers:</b></p><p>Global Blood Therapeutics (NASDAQ: GBT) 30% HIGHER; said to draw takeover interest - Bloomberg</p><p><a href=\"https://laohu8.com/S/YELL\">Yellow Corporation</a> (NASDAQ: YELL) 27% HIGHER; reported Q2 EPS of $1.17, $0.72 better than the analyst estimate of $0.45. Revenue for the quarter came in at $1.42 billion versus the consensus estimate of $1.4 billion.</p><p>Lucid Group (NASDAQ: LCID) 12% LOWER; reported Q2 EPS of ($0.33), $0.06 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $97.3 million versus the consensus estimate of $145.49 million.</p><p><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> (NASDAQ: MELI) 12% HIGHER; reported Q2 EPS of $2.43, $0.50 better than the analyst estimate of $1.93. Revenue for the quarter came in at $2.6 billion versus the consensus estimate of $2.51 billion.</p><p>Skillz (NYSE: SKLZ) 12% LOWER; reported Q2 EPS of ($0.15), in-line with the analyst estimate of ($0.15). Revenue for the quarter came in at $93 million versus the consensus estimate of $92.8 million. Skillz sees FY2022 EPS of $275.00, versus the consensus of $399.13.</p><p>Medifast (NYSE: MED) 11% LOWER; reported Q2 EPS of $3.87, $0.64 better than the analyst estimate of $3.23. Revenue for the quarter came in at $453.3 million versus the consensus estimate of $447.87 million. Medifast sees FY2022 EPS of $12.70-$14.10, versus the consensus of $15.38. Medifast sees FY2022 revenue of $1.58-1.66 billion, versus the consensus of $1.8 billion.</p><p>Fortinet (NASDAQ: FTNT) 9% LOWER; reported Q2 EPS of $0.24, $0.02 better than the analyst estimate of $0.22. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $1.03 billion. Fortinet sees Q3 2022 EPS of $0.26-$0.28, versus the consensus of $0.27. Fortinet sees Q3 2022 revenue of $1.105-1.135 billion, versus the consensus of $1.12 billion. Fortinet sees FY2022 EPS of $1.01-$1.06, versus the consensus of $1.03. Fortinet sees FY2022 revenue of $4.35-4.4 billion, versus the consensus of $4.38 billion.</p><p>PacBio (NASDAQ: PACB) 8% LOWER; Q2 Revenue of $35.5 million, a 16% increase compared with $30.6 million in the prior year period.</p><p>Clorox (NYSE: CLX) 6% LOWER; reported Q4 EPS of $0.93, in-line with the analyst estimate of $0.93. Revenue for the quarter came in at $1.8 billion versus the consensus estimate of $1.86 billion. Clorox sees FY2023 EPS of $3.82-$4.22, versus the consensus of $5.26.</p><p><a href=\"https://laohu8.com/S/LUMN\">Lumen Technologies</a> (NYSE: LUMN) 6% LOWER; reported Q2 EPS of $0.35, $0.11 worse than the analyst estimate of $0.46. Revenue for the quarter came in at $4.61 billion versus the consensus estimate of $4.58 billion. The company reiterated its full-year 2022 financial outlook</p><p>Albemarle (NYSE: ALB) 5% HIGHER; reported Q2 EPS of $3.45, $0.45 better than the analyst estimate of $3.00. Revenue for the quarter came in at $1.48 billion versus the consensus estimate of $1.43 billion. Albemarle sees FY2022 EPS of $19.25-$22.25, versus the consensus of $15.87. Albemarle sees FY2022 revenue of $7.1-7.5 billion, versus the consensus of $6.89 billion.</p><p>Sunrun (NASDAQ: RUN) 5% HIGHER; reported Q2 EPS of ($0.06), $0.07 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $584.6 million versus the consensus estimate of $501.53 million.</p><p>Qorvo (NASDAQ: QRVO) 4% LOWER; reported Q1 EPS of $2.25, $0.14 better than the analyst estimate of $2.11. Revenue for the quarter came in at $1.04 billion versus the consensus estimate of $1.02 billion. Qorvo sees Q2 2023 EPS of $2.45-$2.65, versus the consensus of $2.64. Qorvo sees Q2 2023 revenue of $1.12-1.15 billion, versus the consensus of $1.14 billion.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Movers: GBT Gains on Takeover Chatter, Lucid Falls Following Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Movers: GBT Gains on Takeover Chatter, Lucid Falls Following Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-04 07:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=20412907><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Global Blood Therapeutics (NASDAQ: GBT) 30% HIGHER; said to draw takeover interest - BloombergYellow Corporation (NASDAQ: YELL) 27% HIGHER; reported Q2 EPS of $1.17, $0.72 ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=20412907\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.streetinsider.com/dr/news.php?id=20412907","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2256914424","content_text":"After-Hours Stock Movers:Global Blood Therapeutics (NASDAQ: GBT) 30% HIGHER; said to draw takeover interest - BloombergYellow Corporation (NASDAQ: YELL) 27% HIGHER; reported Q2 EPS of $1.17, $0.72 better than the analyst estimate of $0.45. Revenue for the quarter came in at $1.42 billion versus the consensus estimate of $1.4 billion.Lucid Group (NASDAQ: LCID) 12% LOWER; reported Q2 EPS of ($0.33), $0.06 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $97.3 million versus the consensus estimate of $145.49 million.MercadoLibre (NASDAQ: MELI) 12% HIGHER; reported Q2 EPS of $2.43, $0.50 better than the analyst estimate of $1.93. Revenue for the quarter came in at $2.6 billion versus the consensus estimate of $2.51 billion.Skillz (NYSE: SKLZ) 12% LOWER; reported Q2 EPS of ($0.15), in-line with the analyst estimate of ($0.15). Revenue for the quarter came in at $93 million versus the consensus estimate of $92.8 million. Skillz sees FY2022 EPS of $275.00, versus the consensus of $399.13.Medifast (NYSE: MED) 11% LOWER; reported Q2 EPS of $3.87, $0.64 better than the analyst estimate of $3.23. Revenue for the quarter came in at $453.3 million versus the consensus estimate of $447.87 million. Medifast sees FY2022 EPS of $12.70-$14.10, versus the consensus of $15.38. Medifast sees FY2022 revenue of $1.58-1.66 billion, versus the consensus of $1.8 billion.Fortinet (NASDAQ: FTNT) 9% LOWER; reported Q2 EPS of $0.24, $0.02 better than the analyst estimate of $0.22. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $1.03 billion. Fortinet sees Q3 2022 EPS of $0.26-$0.28, versus the consensus of $0.27. Fortinet sees Q3 2022 revenue of $1.105-1.135 billion, versus the consensus of $1.12 billion. Fortinet sees FY2022 EPS of $1.01-$1.06, versus the consensus of $1.03. Fortinet sees FY2022 revenue of $4.35-4.4 billion, versus the consensus of $4.38 billion.PacBio (NASDAQ: PACB) 8% LOWER; Q2 Revenue of $35.5 million, a 16% increase compared with $30.6 million in the prior year period.Clorox (NYSE: CLX) 6% LOWER; reported Q4 EPS of $0.93, in-line with the analyst estimate of $0.93. Revenue for the quarter came in at $1.8 billion versus the consensus estimate of $1.86 billion. Clorox sees FY2023 EPS of $3.82-$4.22, versus the consensus of $5.26.Lumen Technologies (NYSE: LUMN) 6% LOWER; reported Q2 EPS of $0.35, $0.11 worse than the analyst estimate of $0.46. Revenue for the quarter came in at $4.61 billion versus the consensus estimate of $4.58 billion. The company reiterated its full-year 2022 financial outlookAlbemarle (NYSE: ALB) 5% HIGHER; reported Q2 EPS of $3.45, $0.45 better than the analyst estimate of $3.00. Revenue for the quarter came in at $1.48 billion versus the consensus estimate of $1.43 billion. Albemarle sees FY2022 EPS of $19.25-$22.25, versus the consensus of $15.87. Albemarle sees FY2022 revenue of $7.1-7.5 billion, versus the consensus of $6.89 billion.Sunrun (NASDAQ: RUN) 5% HIGHER; reported Q2 EPS of ($0.06), $0.07 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $584.6 million versus the consensus estimate of $501.53 million.Qorvo (NASDAQ: QRVO) 4% LOWER; reported Q1 EPS of $2.25, $0.14 better than the analyst estimate of $2.11. Revenue for the quarter came in at $1.04 billion versus the consensus estimate of $1.02 billion. Qorvo sees Q2 2023 EPS of $2.45-$2.65, versus the consensus of $2.64. Qorvo sees Q2 2023 revenue of $1.12-1.15 billion, versus the consensus of $1.14 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9906475576,"gmtCreate":1659583473098,"gmtModify":1705981917711,"author":{"id":"3584006131453100","authorId":"3584006131453100","name":"74rk","avatar":"https://static.tigerbbs.com/5d2cbf8ec63fa4fc1ffb7189ba15e1bc","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":0,"idStr":"3584006131453100","authorIdStr":"3584006131453100"},"htmlText":"9","listText":"9","text":"9","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9906475576","repostId":2256914424,"repostType":4,"repost":{"id":"2256914424","kind":"highlight","pubTimestamp":1659569267,"share":"https://ttm.financial/m/news/2256914424?lang=&edition=full_marsco","pubTime":"2022-08-04 07:27","market":"us","language":"en","title":"After-Hours Movers: GBT Gains on Takeover Chatter, Lucid Falls Following Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2256914424","media":"StreetInsider","summary":"After-Hours Stock Movers:Global Blood Therapeutics (NASDAQ: GBT) 30% HIGHER; said to draw takeover i","content":"<html><head></head><body><p><img src=\"https://static.tigerbbs.com/9609a375d55501d49f219b3fd7adbb75\" tg-width=\"200\" tg-height=\"134\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p><b>After-Hours Stock Movers:</b></p><p>Global Blood Therapeutics (NASDAQ: GBT) 30% HIGHER; said to draw takeover interest - Bloomberg</p><p><a href=\"https://laohu8.com/S/YELL\">Yellow Corporation</a> (NASDAQ: YELL) 27% HIGHER; reported Q2 EPS of $1.17, $0.72 better than the analyst estimate of $0.45. Revenue for the quarter came in at $1.42 billion versus the consensus estimate of $1.4 billion.</p><p>Lucid Group (NASDAQ: LCID) 12% LOWER; reported Q2 EPS of ($0.33), $0.06 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $97.3 million versus the consensus estimate of $145.49 million.</p><p><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> (NASDAQ: MELI) 12% HIGHER; reported Q2 EPS of $2.43, $0.50 better than the analyst estimate of $1.93. Revenue for the quarter came in at $2.6 billion versus the consensus estimate of $2.51 billion.</p><p>Skillz (NYSE: SKLZ) 12% LOWER; reported Q2 EPS of ($0.15), in-line with the analyst estimate of ($0.15). Revenue for the quarter came in at $93 million versus the consensus estimate of $92.8 million. Skillz sees FY2022 EPS of $275.00, versus the consensus of $399.13.</p><p>Medifast (NYSE: MED) 11% LOWER; reported Q2 EPS of $3.87, $0.64 better than the analyst estimate of $3.23. Revenue for the quarter came in at $453.3 million versus the consensus estimate of $447.87 million. Medifast sees FY2022 EPS of $12.70-$14.10, versus the consensus of $15.38. Medifast sees FY2022 revenue of $1.58-1.66 billion, versus the consensus of $1.8 billion.</p><p>Fortinet (NASDAQ: FTNT) 9% LOWER; reported Q2 EPS of $0.24, $0.02 better than the analyst estimate of $0.22. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $1.03 billion. Fortinet sees Q3 2022 EPS of $0.26-$0.28, versus the consensus of $0.27. Fortinet sees Q3 2022 revenue of $1.105-1.135 billion, versus the consensus of $1.12 billion. Fortinet sees FY2022 EPS of $1.01-$1.06, versus the consensus of $1.03. Fortinet sees FY2022 revenue of $4.35-4.4 billion, versus the consensus of $4.38 billion.</p><p>PacBio (NASDAQ: PACB) 8% LOWER; Q2 Revenue of $35.5 million, a 16% increase compared with $30.6 million in the prior year period.</p><p>Clorox (NYSE: CLX) 6% LOWER; reported Q4 EPS of $0.93, in-line with the analyst estimate of $0.93. Revenue for the quarter came in at $1.8 billion versus the consensus estimate of $1.86 billion. Clorox sees FY2023 EPS of $3.82-$4.22, versus the consensus of $5.26.</p><p><a href=\"https://laohu8.com/S/LUMN\">Lumen Technologies</a> (NYSE: LUMN) 6% LOWER; reported Q2 EPS of $0.35, $0.11 worse than the analyst estimate of $0.46. Revenue for the quarter came in at $4.61 billion versus the consensus estimate of $4.58 billion. The company reiterated its full-year 2022 financial outlook</p><p>Albemarle (NYSE: ALB) 5% HIGHER; reported Q2 EPS of $3.45, $0.45 better than the analyst estimate of $3.00. Revenue for the quarter came in at $1.48 billion versus the consensus estimate of $1.43 billion. Albemarle sees FY2022 EPS of $19.25-$22.25, versus the consensus of $15.87. Albemarle sees FY2022 revenue of $7.1-7.5 billion, versus the consensus of $6.89 billion.</p><p>Sunrun (NASDAQ: RUN) 5% HIGHER; reported Q2 EPS of ($0.06), $0.07 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $584.6 million versus the consensus estimate of $501.53 million.</p><p>Qorvo (NASDAQ: QRVO) 4% LOWER; reported Q1 EPS of $2.25, $0.14 better than the analyst estimate of $2.11. Revenue for the quarter came in at $1.04 billion versus the consensus estimate of $1.02 billion. Qorvo sees Q2 2023 EPS of $2.45-$2.65, versus the consensus of $2.64. Qorvo sees Q2 2023 revenue of $1.12-1.15 billion, versus the consensus of $1.14 billion.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Movers: GBT Gains on Takeover Chatter, Lucid Falls Following Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Movers: GBT Gains on Takeover Chatter, Lucid Falls Following Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-04 07:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=20412907><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Global Blood Therapeutics (NASDAQ: GBT) 30% HIGHER; said to draw takeover interest - BloombergYellow Corporation (NASDAQ: YELL) 27% HIGHER; reported Q2 EPS of $1.17, $0.72 ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=20412907\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.streetinsider.com/dr/news.php?id=20412907","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2256914424","content_text":"After-Hours Stock Movers:Global Blood Therapeutics (NASDAQ: GBT) 30% HIGHER; said to draw takeover interest - BloombergYellow Corporation (NASDAQ: YELL) 27% HIGHER; reported Q2 EPS of $1.17, $0.72 better than the analyst estimate of $0.45. Revenue for the quarter came in at $1.42 billion versus the consensus estimate of $1.4 billion.Lucid Group (NASDAQ: LCID) 12% LOWER; reported Q2 EPS of ($0.33), $0.06 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $97.3 million versus the consensus estimate of $145.49 million.MercadoLibre (NASDAQ: MELI) 12% HIGHER; reported Q2 EPS of $2.43, $0.50 better than the analyst estimate of $1.93. Revenue for the quarter came in at $2.6 billion versus the consensus estimate of $2.51 billion.Skillz (NYSE: SKLZ) 12% LOWER; reported Q2 EPS of ($0.15), in-line with the analyst estimate of ($0.15). Revenue for the quarter came in at $93 million versus the consensus estimate of $92.8 million. Skillz sees FY2022 EPS of $275.00, versus the consensus of $399.13.Medifast (NYSE: MED) 11% LOWER; reported Q2 EPS of $3.87, $0.64 better than the analyst estimate of $3.23. Revenue for the quarter came in at $453.3 million versus the consensus estimate of $447.87 million. Medifast sees FY2022 EPS of $12.70-$14.10, versus the consensus of $15.38. Medifast sees FY2022 revenue of $1.58-1.66 billion, versus the consensus of $1.8 billion.Fortinet (NASDAQ: FTNT) 9% LOWER; reported Q2 EPS of $0.24, $0.02 better than the analyst estimate of $0.22. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $1.03 billion. Fortinet sees Q3 2022 EPS of $0.26-$0.28, versus the consensus of $0.27. Fortinet sees Q3 2022 revenue of $1.105-1.135 billion, versus the consensus of $1.12 billion. Fortinet sees FY2022 EPS of $1.01-$1.06, versus the consensus of $1.03. Fortinet sees FY2022 revenue of $4.35-4.4 billion, versus the consensus of $4.38 billion.PacBio (NASDAQ: PACB) 8% LOWER; Q2 Revenue of $35.5 million, a 16% increase compared with $30.6 million in the prior year period.Clorox (NYSE: CLX) 6% LOWER; reported Q4 EPS of $0.93, in-line with the analyst estimate of $0.93. Revenue for the quarter came in at $1.8 billion versus the consensus estimate of $1.86 billion. Clorox sees FY2023 EPS of $3.82-$4.22, versus the consensus of $5.26.Lumen Technologies (NYSE: LUMN) 6% LOWER; reported Q2 EPS of $0.35, $0.11 worse than the analyst estimate of $0.46. Revenue for the quarter came in at $4.61 billion versus the consensus estimate of $4.58 billion. The company reiterated its full-year 2022 financial outlookAlbemarle (NYSE: ALB) 5% HIGHER; reported Q2 EPS of $3.45, $0.45 better than the analyst estimate of $3.00. Revenue for the quarter came in at $1.48 billion versus the consensus estimate of $1.43 billion. Albemarle sees FY2022 EPS of $19.25-$22.25, versus the consensus of $15.87. Albemarle sees FY2022 revenue of $7.1-7.5 billion, versus the consensus of $6.89 billion.Sunrun (NASDAQ: RUN) 5% HIGHER; reported Q2 EPS of ($0.06), $0.07 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $584.6 million versus the consensus estimate of $501.53 million.Qorvo (NASDAQ: QRVO) 4% LOWER; reported Q1 EPS of $2.25, $0.14 better than the analyst estimate of $2.11. Revenue for the quarter came in at $1.04 billion versus the consensus estimate of $1.02 billion. Qorvo sees Q2 2023 EPS of $2.45-$2.65, versus the consensus of $2.64. Qorvo sees Q2 2023 revenue of $1.12-1.15 billion, versus the consensus of $1.14 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9906455877,"gmtCreate":1659581306602,"gmtModify":1705981884509,"author":{"id":"3582098623642517","authorId":"3582098623642517","name":"小虎一飞冲天","avatar":"https://static.tigerbbs.com/1a55a61195830e019abf5d3cc69681b9","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3582098623642517","authorIdStr":"3582098623642517"},"htmlText":"Like pls&nbsp;","listText":"Like pls&nbsp;","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9906455877","repostId":2256914424,"repostType":4,"repost":{"id":"2256914424","kind":"highlight","pubTimestamp":1659569267,"share":"https://ttm.financial/m/news/2256914424?lang=&edition=full_marsco","pubTime":"2022-08-04 07:27","market":"us","language":"en","title":"After-Hours Movers: GBT Gains on Takeover Chatter, Lucid Falls Following Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2256914424","media":"StreetInsider","summary":"After-Hours Stock Movers:Global Blood Therapeutics (NASDAQ: GBT) 30% HIGHER; said to draw takeover i","content":"<html><head></head><body><p><img src=\"https://static.tigerbbs.com/9609a375d55501d49f219b3fd7adbb75\" tg-width=\"200\" tg-height=\"134\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p><b>After-Hours Stock Movers:</b></p><p>Global Blood Therapeutics (NASDAQ: GBT) 30% HIGHER; said to draw takeover interest - Bloomberg</p><p><a href=\"https://laohu8.com/S/YELL\">Yellow Corporation</a> (NASDAQ: YELL) 27% HIGHER; reported Q2 EPS of $1.17, $0.72 better than the analyst estimate of $0.45. Revenue for the quarter came in at $1.42 billion versus the consensus estimate of $1.4 billion.</p><p>Lucid Group (NASDAQ: LCID) 12% LOWER; reported Q2 EPS of ($0.33), $0.06 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $97.3 million versus the consensus estimate of $145.49 million.</p><p><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> (NASDAQ: MELI) 12% HIGHER; reported Q2 EPS of $2.43, $0.50 better than the analyst estimate of $1.93. Revenue for the quarter came in at $2.6 billion versus the consensus estimate of $2.51 billion.</p><p>Skillz (NYSE: SKLZ) 12% LOWER; reported Q2 EPS of ($0.15), in-line with the analyst estimate of ($0.15). Revenue for the quarter came in at $93 million versus the consensus estimate of $92.8 million. Skillz sees FY2022 EPS of $275.00, versus the consensus of $399.13.</p><p>Medifast (NYSE: MED) 11% LOWER; reported Q2 EPS of $3.87, $0.64 better than the analyst estimate of $3.23. Revenue for the quarter came in at $453.3 million versus the consensus estimate of $447.87 million. Medifast sees FY2022 EPS of $12.70-$14.10, versus the consensus of $15.38. Medifast sees FY2022 revenue of $1.58-1.66 billion, versus the consensus of $1.8 billion.</p><p>Fortinet (NASDAQ: FTNT) 9% LOWER; reported Q2 EPS of $0.24, $0.02 better than the analyst estimate of $0.22. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $1.03 billion. Fortinet sees Q3 2022 EPS of $0.26-$0.28, versus the consensus of $0.27. Fortinet sees Q3 2022 revenue of $1.105-1.135 billion, versus the consensus of $1.12 billion. Fortinet sees FY2022 EPS of $1.01-$1.06, versus the consensus of $1.03. Fortinet sees FY2022 revenue of $4.35-4.4 billion, versus the consensus of $4.38 billion.</p><p>PacBio (NASDAQ: PACB) 8% LOWER; Q2 Revenue of $35.5 million, a 16% increase compared with $30.6 million in the prior year period.</p><p>Clorox (NYSE: CLX) 6% LOWER; reported Q4 EPS of $0.93, in-line with the analyst estimate of $0.93. Revenue for the quarter came in at $1.8 billion versus the consensus estimate of $1.86 billion. Clorox sees FY2023 EPS of $3.82-$4.22, versus the consensus of $5.26.</p><p><a href=\"https://laohu8.com/S/LUMN\">Lumen Technologies</a> (NYSE: LUMN) 6% LOWER; reported Q2 EPS of $0.35, $0.11 worse than the analyst estimate of $0.46. Revenue for the quarter came in at $4.61 billion versus the consensus estimate of $4.58 billion. The company reiterated its full-year 2022 financial outlook</p><p>Albemarle (NYSE: ALB) 5% HIGHER; reported Q2 EPS of $3.45, $0.45 better than the analyst estimate of $3.00. Revenue for the quarter came in at $1.48 billion versus the consensus estimate of $1.43 billion. Albemarle sees FY2022 EPS of $19.25-$22.25, versus the consensus of $15.87. Albemarle sees FY2022 revenue of $7.1-7.5 billion, versus the consensus of $6.89 billion.</p><p>Sunrun (NASDAQ: RUN) 5% HIGHER; reported Q2 EPS of ($0.06), $0.07 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $584.6 million versus the consensus estimate of $501.53 million.</p><p>Qorvo (NASDAQ: QRVO) 4% LOWER; reported Q1 EPS of $2.25, $0.14 better than the analyst estimate of $2.11. Revenue for the quarter came in at $1.04 billion versus the consensus estimate of $1.02 billion. Qorvo sees Q2 2023 EPS of $2.45-$2.65, versus the consensus of $2.64. Qorvo sees Q2 2023 revenue of $1.12-1.15 billion, versus the consensus of $1.14 billion.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Movers: GBT Gains on Takeover Chatter, Lucid Falls Following Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Movers: GBT Gains on Takeover Chatter, Lucid Falls Following Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-04 07:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=20412907><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Global Blood Therapeutics (NASDAQ: GBT) 30% HIGHER; said to draw takeover interest - BloombergYellow Corporation (NASDAQ: YELL) 27% HIGHER; reported Q2 EPS of $1.17, $0.72 ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=20412907\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.streetinsider.com/dr/news.php?id=20412907","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2256914424","content_text":"After-Hours Stock Movers:Global Blood Therapeutics (NASDAQ: GBT) 30% HIGHER; said to draw takeover interest - BloombergYellow Corporation (NASDAQ: YELL) 27% HIGHER; reported Q2 EPS of $1.17, $0.72 better than the analyst estimate of $0.45. Revenue for the quarter came in at $1.42 billion versus the consensus estimate of $1.4 billion.Lucid Group (NASDAQ: LCID) 12% LOWER; reported Q2 EPS of ($0.33), $0.06 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $97.3 million versus the consensus estimate of $145.49 million.MercadoLibre (NASDAQ: MELI) 12% HIGHER; reported Q2 EPS of $2.43, $0.50 better than the analyst estimate of $1.93. Revenue for the quarter came in at $2.6 billion versus the consensus estimate of $2.51 billion.Skillz (NYSE: SKLZ) 12% LOWER; reported Q2 EPS of ($0.15), in-line with the analyst estimate of ($0.15). Revenue for the quarter came in at $93 million versus the consensus estimate of $92.8 million. Skillz sees FY2022 EPS of $275.00, versus the consensus of $399.13.Medifast (NYSE: MED) 11% LOWER; reported Q2 EPS of $3.87, $0.64 better than the analyst estimate of $3.23. Revenue for the quarter came in at $453.3 million versus the consensus estimate of $447.87 million. Medifast sees FY2022 EPS of $12.70-$14.10, versus the consensus of $15.38. Medifast sees FY2022 revenue of $1.58-1.66 billion, versus the consensus of $1.8 billion.Fortinet (NASDAQ: FTNT) 9% LOWER; reported Q2 EPS of $0.24, $0.02 better than the analyst estimate of $0.22. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $1.03 billion. Fortinet sees Q3 2022 EPS of $0.26-$0.28, versus the consensus of $0.27. Fortinet sees Q3 2022 revenue of $1.105-1.135 billion, versus the consensus of $1.12 billion. Fortinet sees FY2022 EPS of $1.01-$1.06, versus the consensus of $1.03. Fortinet sees FY2022 revenue of $4.35-4.4 billion, versus the consensus of $4.38 billion.PacBio (NASDAQ: PACB) 8% LOWER; Q2 Revenue of $35.5 million, a 16% increase compared with $30.6 million in the prior year period.Clorox (NYSE: CLX) 6% LOWER; reported Q4 EPS of $0.93, in-line with the analyst estimate of $0.93. Revenue for the quarter came in at $1.8 billion versus the consensus estimate of $1.86 billion. Clorox sees FY2023 EPS of $3.82-$4.22, versus the consensus of $5.26.Lumen Technologies (NYSE: LUMN) 6% LOWER; reported Q2 EPS of $0.35, $0.11 worse than the analyst estimate of $0.46. Revenue for the quarter came in at $4.61 billion versus the consensus estimate of $4.58 billion. The company reiterated its full-year 2022 financial outlookAlbemarle (NYSE: ALB) 5% HIGHER; reported Q2 EPS of $3.45, $0.45 better than the analyst estimate of $3.00. Revenue for the quarter came in at $1.48 billion versus the consensus estimate of $1.43 billion. Albemarle sees FY2022 EPS of $19.25-$22.25, versus the consensus of $15.87. Albemarle sees FY2022 revenue of $7.1-7.5 billion, versus the consensus of $6.89 billion.Sunrun (NASDAQ: RUN) 5% HIGHER; reported Q2 EPS of ($0.06), $0.07 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $584.6 million versus the consensus estimate of $501.53 million.Qorvo (NASDAQ: QRVO) 4% LOWER; reported Q1 EPS of $2.25, $0.14 better than the analyst estimate of $2.11. Revenue for the quarter came in at $1.04 billion versus the consensus estimate of $1.02 billion. Qorvo sees Q2 2023 EPS of $2.45-$2.65, versus the consensus of $2.64. Qorvo sees Q2 2023 revenue of $1.12-1.15 billion, versus the consensus of $1.14 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9906451925,"gmtCreate":1659580663769,"gmtModify":1705981877462,"author":{"id":"4100437715079400","authorId":"4100437715079400","name":"Looyusooi","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"4100437715079400","authorIdStr":"4100437715079400"},"htmlText":"Ok&nbsp;","listText":"Ok&nbsp;","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9906451925","repostId":2256914424,"repostType":4,"repost":{"id":"2256914424","kind":"highlight","pubTimestamp":1659569267,"share":"https://ttm.financial/m/news/2256914424?lang=&edition=full_marsco","pubTime":"2022-08-04 07:27","market":"us","language":"en","title":"After-Hours Movers: GBT Gains on Takeover Chatter, Lucid Falls Following Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2256914424","media":"StreetInsider","summary":"After-Hours Stock Movers:Global Blood Therapeutics (NASDAQ: GBT) 30% HIGHER; said to draw takeover i","content":"<html><head></head><body><p><img src=\"https://static.tigerbbs.com/9609a375d55501d49f219b3fd7adbb75\" tg-width=\"200\" tg-height=\"134\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p><b>After-Hours Stock Movers:</b></p><p>Global Blood Therapeutics (NASDAQ: GBT) 30% HIGHER; said to draw takeover interest - Bloomberg</p><p><a href=\"https://laohu8.com/S/YELL\">Yellow Corporation</a> (NASDAQ: YELL) 27% HIGHER; reported Q2 EPS of $1.17, $0.72 better than the analyst estimate of $0.45. Revenue for the quarter came in at $1.42 billion versus the consensus estimate of $1.4 billion.</p><p>Lucid Group (NASDAQ: LCID) 12% LOWER; reported Q2 EPS of ($0.33), $0.06 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $97.3 million versus the consensus estimate of $145.49 million.</p><p><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> (NASDAQ: MELI) 12% HIGHER; reported Q2 EPS of $2.43, $0.50 better than the analyst estimate of $1.93. Revenue for the quarter came in at $2.6 billion versus the consensus estimate of $2.51 billion.</p><p>Skillz (NYSE: SKLZ) 12% LOWER; reported Q2 EPS of ($0.15), in-line with the analyst estimate of ($0.15). Revenue for the quarter came in at $93 million versus the consensus estimate of $92.8 million. Skillz sees FY2022 EPS of $275.00, versus the consensus of $399.13.</p><p>Medifast (NYSE: MED) 11% LOWER; reported Q2 EPS of $3.87, $0.64 better than the analyst estimate of $3.23. Revenue for the quarter came in at $453.3 million versus the consensus estimate of $447.87 million. Medifast sees FY2022 EPS of $12.70-$14.10, versus the consensus of $15.38. Medifast sees FY2022 revenue of $1.58-1.66 billion, versus the consensus of $1.8 billion.</p><p>Fortinet (NASDAQ: FTNT) 9% LOWER; reported Q2 EPS of $0.24, $0.02 better than the analyst estimate of $0.22. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $1.03 billion. Fortinet sees Q3 2022 EPS of $0.26-$0.28, versus the consensus of $0.27. Fortinet sees Q3 2022 revenue of $1.105-1.135 billion, versus the consensus of $1.12 billion. Fortinet sees FY2022 EPS of $1.01-$1.06, versus the consensus of $1.03. Fortinet sees FY2022 revenue of $4.35-4.4 billion, versus the consensus of $4.38 billion.</p><p>PacBio (NASDAQ: PACB) 8% LOWER; Q2 Revenue of $35.5 million, a 16% increase compared with $30.6 million in the prior year period.</p><p>Clorox (NYSE: CLX) 6% LOWER; reported Q4 EPS of $0.93, in-line with the analyst estimate of $0.93. Revenue for the quarter came in at $1.8 billion versus the consensus estimate of $1.86 billion. Clorox sees FY2023 EPS of $3.82-$4.22, versus the consensus of $5.26.</p><p><a href=\"https://laohu8.com/S/LUMN\">Lumen Technologies</a> (NYSE: LUMN) 6% LOWER; reported Q2 EPS of $0.35, $0.11 worse than the analyst estimate of $0.46. Revenue for the quarter came in at $4.61 billion versus the consensus estimate of $4.58 billion. The company reiterated its full-year 2022 financial outlook</p><p>Albemarle (NYSE: ALB) 5% HIGHER; reported Q2 EPS of $3.45, $0.45 better than the analyst estimate of $3.00. Revenue for the quarter came in at $1.48 billion versus the consensus estimate of $1.43 billion. Albemarle sees FY2022 EPS of $19.25-$22.25, versus the consensus of $15.87. Albemarle sees FY2022 revenue of $7.1-7.5 billion, versus the consensus of $6.89 billion.</p><p>Sunrun (NASDAQ: RUN) 5% HIGHER; reported Q2 EPS of ($0.06), $0.07 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $584.6 million versus the consensus estimate of $501.53 million.</p><p>Qorvo (NASDAQ: QRVO) 4% LOWER; reported Q1 EPS of $2.25, $0.14 better than the analyst estimate of $2.11. Revenue for the quarter came in at $1.04 billion versus the consensus estimate of $1.02 billion. Qorvo sees Q2 2023 EPS of $2.45-$2.65, versus the consensus of $2.64. Qorvo sees Q2 2023 revenue of $1.12-1.15 billion, versus the consensus of $1.14 billion.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Movers: GBT Gains on Takeover Chatter, Lucid Falls Following Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Movers: GBT Gains on Takeover Chatter, Lucid Falls Following Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-04 07:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=20412907><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Global Blood Therapeutics (NASDAQ: GBT) 30% HIGHER; said to draw takeover interest - BloombergYellow Corporation (NASDAQ: YELL) 27% HIGHER; reported Q2 EPS of $1.17, $0.72 ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=20412907\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.streetinsider.com/dr/news.php?id=20412907","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2256914424","content_text":"After-Hours Stock Movers:Global Blood Therapeutics (NASDAQ: GBT) 30% HIGHER; said to draw takeover interest - BloombergYellow Corporation (NASDAQ: YELL) 27% HIGHER; reported Q2 EPS of $1.17, $0.72 better than the analyst estimate of $0.45. Revenue for the quarter came in at $1.42 billion versus the consensus estimate of $1.4 billion.Lucid Group (NASDAQ: LCID) 12% LOWER; reported Q2 EPS of ($0.33), $0.06 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $97.3 million versus the consensus estimate of $145.49 million.MercadoLibre (NASDAQ: MELI) 12% HIGHER; reported Q2 EPS of $2.43, $0.50 better than the analyst estimate of $1.93. Revenue for the quarter came in at $2.6 billion versus the consensus estimate of $2.51 billion.Skillz (NYSE: SKLZ) 12% LOWER; reported Q2 EPS of ($0.15), in-line with the analyst estimate of ($0.15). Revenue for the quarter came in at $93 million versus the consensus estimate of $92.8 million. Skillz sees FY2022 EPS of $275.00, versus the consensus of $399.13.Medifast (NYSE: MED) 11% LOWER; reported Q2 EPS of $3.87, $0.64 better than the analyst estimate of $3.23. Revenue for the quarter came in at $453.3 million versus the consensus estimate of $447.87 million. Medifast sees FY2022 EPS of $12.70-$14.10, versus the consensus of $15.38. Medifast sees FY2022 revenue of $1.58-1.66 billion, versus the consensus of $1.8 billion.Fortinet (NASDAQ: FTNT) 9% LOWER; reported Q2 EPS of $0.24, $0.02 better than the analyst estimate of $0.22. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $1.03 billion. Fortinet sees Q3 2022 EPS of $0.26-$0.28, versus the consensus of $0.27. Fortinet sees Q3 2022 revenue of $1.105-1.135 billion, versus the consensus of $1.12 billion. Fortinet sees FY2022 EPS of $1.01-$1.06, versus the consensus of $1.03. Fortinet sees FY2022 revenue of $4.35-4.4 billion, versus the consensus of $4.38 billion.PacBio (NASDAQ: PACB) 8% LOWER; Q2 Revenue of $35.5 million, a 16% increase compared with $30.6 million in the prior year period.Clorox (NYSE: CLX) 6% LOWER; reported Q4 EPS of $0.93, in-line with the analyst estimate of $0.93. Revenue for the quarter came in at $1.8 billion versus the consensus estimate of $1.86 billion. Clorox sees FY2023 EPS of $3.82-$4.22, versus the consensus of $5.26.Lumen Technologies (NYSE: LUMN) 6% LOWER; reported Q2 EPS of $0.35, $0.11 worse than the analyst estimate of $0.46. Revenue for the quarter came in at $4.61 billion versus the consensus estimate of $4.58 billion. The company reiterated its full-year 2022 financial outlookAlbemarle (NYSE: ALB) 5% HIGHER; reported Q2 EPS of $3.45, $0.45 better than the analyst estimate of $3.00. Revenue for the quarter came in at $1.48 billion versus the consensus estimate of $1.43 billion. Albemarle sees FY2022 EPS of $19.25-$22.25, versus the consensus of $15.87. Albemarle sees FY2022 revenue of $7.1-7.5 billion, versus the consensus of $6.89 billion.Sunrun (NASDAQ: RUN) 5% HIGHER; reported Q2 EPS of ($0.06), $0.07 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $584.6 million versus the consensus estimate of $501.53 million.Qorvo (NASDAQ: QRVO) 4% LOWER; reported Q1 EPS of $2.25, $0.14 better than the analyst estimate of $2.11. Revenue for the quarter came in at $1.04 billion versus the consensus estimate of $1.02 billion. Qorvo sees Q2 2023 EPS of $2.45-$2.65, versus the consensus of $2.64. Qorvo sees Q2 2023 revenue of $1.12-1.15 billion, versus the consensus of $1.14 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9906434502,"gmtCreate":1659576803509,"gmtModify":1705981805112,"author":{"id":"3579002978614578","authorId":"3579002978614578","name":"Geoz88","avatar":"https://static.tigerbbs.com/40716588ae7919100620a5b5a9c48cac","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":5,"crmLevelSwitch":1,"idStr":"3579002978614578","authorIdStr":"3579002978614578"},"htmlText":"Yes&nbsp;","listText":"Yes&nbsp;","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9906434502","repostId":2256914424,"repostType":4,"repost":{"id":"2256914424","kind":"highlight","pubTimestamp":1659569267,"share":"https://ttm.financial/m/news/2256914424?lang=&edition=full_marsco","pubTime":"2022-08-04 07:27","market":"us","language":"en","title":"After-Hours Movers: GBT Gains on Takeover Chatter, Lucid Falls Following Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2256914424","media":"StreetInsider","summary":"After-Hours Stock Movers:Global Blood Therapeutics (NASDAQ: GBT) 30% HIGHER; said to draw takeover i","content":"<html><head></head><body><p><img src=\"https://static.tigerbbs.com/9609a375d55501d49f219b3fd7adbb75\" tg-width=\"200\" tg-height=\"134\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p><b>After-Hours Stock Movers:</b></p><p>Global Blood Therapeutics (NASDAQ: GBT) 30% HIGHER; said to draw takeover interest - Bloomberg</p><p><a href=\"https://laohu8.com/S/YELL\">Yellow Corporation</a> (NASDAQ: YELL) 27% HIGHER; reported Q2 EPS of $1.17, $0.72 better than the analyst estimate of $0.45. Revenue for the quarter came in at $1.42 billion versus the consensus estimate of $1.4 billion.</p><p>Lucid Group (NASDAQ: LCID) 12% LOWER; reported Q2 EPS of ($0.33), $0.06 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $97.3 million versus the consensus estimate of $145.49 million.</p><p><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> (NASDAQ: MELI) 12% HIGHER; reported Q2 EPS of $2.43, $0.50 better than the analyst estimate of $1.93. Revenue for the quarter came in at $2.6 billion versus the consensus estimate of $2.51 billion.</p><p>Skillz (NYSE: SKLZ) 12% LOWER; reported Q2 EPS of ($0.15), in-line with the analyst estimate of ($0.15). Revenue for the quarter came in at $93 million versus the consensus estimate of $92.8 million. Skillz sees FY2022 EPS of $275.00, versus the consensus of $399.13.</p><p>Medifast (NYSE: MED) 11% LOWER; reported Q2 EPS of $3.87, $0.64 better than the analyst estimate of $3.23. Revenue for the quarter came in at $453.3 million versus the consensus estimate of $447.87 million. Medifast sees FY2022 EPS of $12.70-$14.10, versus the consensus of $15.38. Medifast sees FY2022 revenue of $1.58-1.66 billion, versus the consensus of $1.8 billion.</p><p>Fortinet (NASDAQ: FTNT) 9% LOWER; reported Q2 EPS of $0.24, $0.02 better than the analyst estimate of $0.22. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $1.03 billion. Fortinet sees Q3 2022 EPS of $0.26-$0.28, versus the consensus of $0.27. Fortinet sees Q3 2022 revenue of $1.105-1.135 billion, versus the consensus of $1.12 billion. Fortinet sees FY2022 EPS of $1.01-$1.06, versus the consensus of $1.03. Fortinet sees FY2022 revenue of $4.35-4.4 billion, versus the consensus of $4.38 billion.</p><p>PacBio (NASDAQ: PACB) 8% LOWER; Q2 Revenue of $35.5 million, a 16% increase compared with $30.6 million in the prior year period.</p><p>Clorox (NYSE: CLX) 6% LOWER; reported Q4 EPS of $0.93, in-line with the analyst estimate of $0.93. Revenue for the quarter came in at $1.8 billion versus the consensus estimate of $1.86 billion. Clorox sees FY2023 EPS of $3.82-$4.22, versus the consensus of $5.26.</p><p><a href=\"https://laohu8.com/S/LUMN\">Lumen Technologies</a> (NYSE: LUMN) 6% LOWER; reported Q2 EPS of $0.35, $0.11 worse than the analyst estimate of $0.46. Revenue for the quarter came in at $4.61 billion versus the consensus estimate of $4.58 billion. The company reiterated its full-year 2022 financial outlook</p><p>Albemarle (NYSE: ALB) 5% HIGHER; reported Q2 EPS of $3.45, $0.45 better than the analyst estimate of $3.00. Revenue for the quarter came in at $1.48 billion versus the consensus estimate of $1.43 billion. Albemarle sees FY2022 EPS of $19.25-$22.25, versus the consensus of $15.87. Albemarle sees FY2022 revenue of $7.1-7.5 billion, versus the consensus of $6.89 billion.</p><p>Sunrun (NASDAQ: RUN) 5% HIGHER; reported Q2 EPS of ($0.06), $0.07 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $584.6 million versus the consensus estimate of $501.53 million.</p><p>Qorvo (NASDAQ: QRVO) 4% LOWER; reported Q1 EPS of $2.25, $0.14 better than the analyst estimate of $2.11. Revenue for the quarter came in at $1.04 billion versus the consensus estimate of $1.02 billion. Qorvo sees Q2 2023 EPS of $2.45-$2.65, versus the consensus of $2.64. Qorvo sees Q2 2023 revenue of $1.12-1.15 billion, versus the consensus of $1.14 billion.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Movers: GBT Gains on Takeover Chatter, Lucid Falls Following Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Movers: GBT Gains on Takeover Chatter, Lucid Falls Following Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-04 07:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=20412907><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Global Blood Therapeutics (NASDAQ: GBT) 30% HIGHER; said to draw takeover interest - BloombergYellow Corporation (NASDAQ: YELL) 27% HIGHER; reported Q2 EPS of $1.17, $0.72 ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=20412907\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.streetinsider.com/dr/news.php?id=20412907","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2256914424","content_text":"After-Hours Stock Movers:Global Blood Therapeutics (NASDAQ: GBT) 30% HIGHER; said to draw takeover interest - BloombergYellow Corporation (NASDAQ: YELL) 27% HIGHER; reported Q2 EPS of $1.17, $0.72 better than the analyst estimate of $0.45. Revenue for the quarter came in at $1.42 billion versus the consensus estimate of $1.4 billion.Lucid Group (NASDAQ: LCID) 12% LOWER; reported Q2 EPS of ($0.33), $0.06 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $97.3 million versus the consensus estimate of $145.49 million.MercadoLibre (NASDAQ: MELI) 12% HIGHER; reported Q2 EPS of $2.43, $0.50 better than the analyst estimate of $1.93. Revenue for the quarter came in at $2.6 billion versus the consensus estimate of $2.51 billion.Skillz (NYSE: SKLZ) 12% LOWER; reported Q2 EPS of ($0.15), in-line with the analyst estimate of ($0.15). Revenue for the quarter came in at $93 million versus the consensus estimate of $92.8 million. Skillz sees FY2022 EPS of $275.00, versus the consensus of $399.13.Medifast (NYSE: MED) 11% LOWER; reported Q2 EPS of $3.87, $0.64 better than the analyst estimate of $3.23. Revenue for the quarter came in at $453.3 million versus the consensus estimate of $447.87 million. Medifast sees FY2022 EPS of $12.70-$14.10, versus the consensus of $15.38. Medifast sees FY2022 revenue of $1.58-1.66 billion, versus the consensus of $1.8 billion.Fortinet (NASDAQ: FTNT) 9% LOWER; reported Q2 EPS of $0.24, $0.02 better than the analyst estimate of $0.22. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $1.03 billion. Fortinet sees Q3 2022 EPS of $0.26-$0.28, versus the consensus of $0.27. Fortinet sees Q3 2022 revenue of $1.105-1.135 billion, versus the consensus of $1.12 billion. Fortinet sees FY2022 EPS of $1.01-$1.06, versus the consensus of $1.03. Fortinet sees FY2022 revenue of $4.35-4.4 billion, versus the consensus of $4.38 billion.PacBio (NASDAQ: PACB) 8% LOWER; Q2 Revenue of $35.5 million, a 16% increase compared with $30.6 million in the prior year period.Clorox (NYSE: CLX) 6% LOWER; reported Q4 EPS of $0.93, in-line with the analyst estimate of $0.93. Revenue for the quarter came in at $1.8 billion versus the consensus estimate of $1.86 billion. Clorox sees FY2023 EPS of $3.82-$4.22, versus the consensus of $5.26.Lumen Technologies (NYSE: LUMN) 6% LOWER; reported Q2 EPS of $0.35, $0.11 worse than the analyst estimate of $0.46. Revenue for the quarter came in at $4.61 billion versus the consensus estimate of $4.58 billion. The company reiterated its full-year 2022 financial outlookAlbemarle (NYSE: ALB) 5% HIGHER; reported Q2 EPS of $3.45, $0.45 better than the analyst estimate of $3.00. Revenue for the quarter came in at $1.48 billion versus the consensus estimate of $1.43 billion. Albemarle sees FY2022 EPS of $19.25-$22.25, versus the consensus of $15.87. Albemarle sees FY2022 revenue of $7.1-7.5 billion, versus the consensus of $6.89 billion.Sunrun (NASDAQ: RUN) 5% HIGHER; reported Q2 EPS of ($0.06), $0.07 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $584.6 million versus the consensus estimate of $501.53 million.Qorvo (NASDAQ: QRVO) 4% LOWER; reported Q1 EPS of $2.25, $0.14 better than the analyst estimate of $2.11. Revenue for the quarter came in at $1.04 billion versus the consensus estimate of $1.02 billion. Qorvo sees Q2 2023 EPS of $2.45-$2.65, versus the consensus of $2.64. Qorvo sees Q2 2023 revenue of $1.12-1.15 billion, versus the consensus of $1.14 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":103233377,"gmtCreate":1659581315207,"gmtModify":1663255516625,"authorId":3582098623642517,"author":{"id":3582098623642517,"idStr":"3582098623642517","authorId":3582098623642517,"name":"小虎一飞冲天","avatar":"https://static.tigerbbs.com/1a55a61195830e019abf5d3cc69681b9","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9906434502,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">👍🏼</span>","text":"<span class=\"s1\">👍🏼</span>","html":"<span class=\"s1\">👍🏼</span>"}],"langContent":"EN"},{"id":9906433099,"gmtCreate":1659576219713,"gmtModify":1705981794185,"author":{"id":"4115257325505790","authorId":"4115257325505790","name":"T202311701","avatar":"https://community-static.tradeup.com/news/816311e9879fbae4e952e2a5386f68ca","vip":1,"crmLevel":9,"crmLevelSwitch":0,"idStr":"4115257325505790","authorIdStr":"4115257325505790"},"htmlText":"Ooo","listText":"Ooo","text":"Ooo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9906433099","repostId":2256914424,"repostType":4,"repost":{"id":"2256914424","kind":"highlight","pubTimestamp":1659569267,"share":"https://ttm.financial/m/news/2256914424?lang=&edition=full_marsco","pubTime":"2022-08-04 07:27","market":"us","language":"en","title":"After-Hours Movers: GBT Gains on Takeover Chatter, Lucid Falls Following Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2256914424","media":"StreetInsider","summary":"After-Hours Stock Movers:Global Blood Therapeutics (NASDAQ: GBT) 30% HIGHER; said to draw takeover i","content":"<html><head></head><body><p><img src=\"https://static.tigerbbs.com/9609a375d55501d49f219b3fd7adbb75\" tg-width=\"200\" tg-height=\"134\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p><b>After-Hours Stock Movers:</b></p><p>Global Blood Therapeutics (NASDAQ: GBT) 30% HIGHER; said to draw takeover interest - Bloomberg</p><p><a href=\"https://laohu8.com/S/YELL\">Yellow Corporation</a> (NASDAQ: YELL) 27% HIGHER; reported Q2 EPS of $1.17, $0.72 better than the analyst estimate of $0.45. Revenue for the quarter came in at $1.42 billion versus the consensus estimate of $1.4 billion.</p><p>Lucid Group (NASDAQ: LCID) 12% LOWER; reported Q2 EPS of ($0.33), $0.06 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $97.3 million versus the consensus estimate of $145.49 million.</p><p><a href=\"https://laohu8.com/S/MELI\">MercadoLibre</a> (NASDAQ: MELI) 12% HIGHER; reported Q2 EPS of $2.43, $0.50 better than the analyst estimate of $1.93. Revenue for the quarter came in at $2.6 billion versus the consensus estimate of $2.51 billion.</p><p>Skillz (NYSE: SKLZ) 12% LOWER; reported Q2 EPS of ($0.15), in-line with the analyst estimate of ($0.15). Revenue for the quarter came in at $93 million versus the consensus estimate of $92.8 million. Skillz sees FY2022 EPS of $275.00, versus the consensus of $399.13.</p><p>Medifast (NYSE: MED) 11% LOWER; reported Q2 EPS of $3.87, $0.64 better than the analyst estimate of $3.23. Revenue for the quarter came in at $453.3 million versus the consensus estimate of $447.87 million. Medifast sees FY2022 EPS of $12.70-$14.10, versus the consensus of $15.38. Medifast sees FY2022 revenue of $1.58-1.66 billion, versus the consensus of $1.8 billion.</p><p>Fortinet (NASDAQ: FTNT) 9% LOWER; reported Q2 EPS of $0.24, $0.02 better than the analyst estimate of $0.22. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $1.03 billion. Fortinet sees Q3 2022 EPS of $0.26-$0.28, versus the consensus of $0.27. Fortinet sees Q3 2022 revenue of $1.105-1.135 billion, versus the consensus of $1.12 billion. Fortinet sees FY2022 EPS of $1.01-$1.06, versus the consensus of $1.03. Fortinet sees FY2022 revenue of $4.35-4.4 billion, versus the consensus of $4.38 billion.</p><p>PacBio (NASDAQ: PACB) 8% LOWER; Q2 Revenue of $35.5 million, a 16% increase compared with $30.6 million in the prior year period.</p><p>Clorox (NYSE: CLX) 6% LOWER; reported Q4 EPS of $0.93, in-line with the analyst estimate of $0.93. Revenue for the quarter came in at $1.8 billion versus the consensus estimate of $1.86 billion. Clorox sees FY2023 EPS of $3.82-$4.22, versus the consensus of $5.26.</p><p><a href=\"https://laohu8.com/S/LUMN\">Lumen Technologies</a> (NYSE: LUMN) 6% LOWER; reported Q2 EPS of $0.35, $0.11 worse than the analyst estimate of $0.46. Revenue for the quarter came in at $4.61 billion versus the consensus estimate of $4.58 billion. The company reiterated its full-year 2022 financial outlook</p><p>Albemarle (NYSE: ALB) 5% HIGHER; reported Q2 EPS of $3.45, $0.45 better than the analyst estimate of $3.00. Revenue for the quarter came in at $1.48 billion versus the consensus estimate of $1.43 billion. Albemarle sees FY2022 EPS of $19.25-$22.25, versus the consensus of $15.87. Albemarle sees FY2022 revenue of $7.1-7.5 billion, versus the consensus of $6.89 billion.</p><p>Sunrun (NASDAQ: RUN) 5% HIGHER; reported Q2 EPS of ($0.06), $0.07 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $584.6 million versus the consensus estimate of $501.53 million.</p><p>Qorvo (NASDAQ: QRVO) 4% LOWER; reported Q1 EPS of $2.25, $0.14 better than the analyst estimate of $2.11. Revenue for the quarter came in at $1.04 billion versus the consensus estimate of $1.02 billion. Qorvo sees Q2 2023 EPS of $2.45-$2.65, versus the consensus of $2.64. Qorvo sees Q2 2023 revenue of $1.12-1.15 billion, versus the consensus of $1.14 billion.</p></body></html>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Movers: GBT Gains on Takeover Chatter, Lucid Falls Following Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Movers: GBT Gains on Takeover Chatter, Lucid Falls Following Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-08-04 07:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=20412907><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:Global Blood Therapeutics (NASDAQ: GBT) 30% HIGHER; said to draw takeover interest - BloombergYellow Corporation (NASDAQ: YELL) 27% HIGHER; reported Q2 EPS of $1.17, $0.72 ...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=20412907\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.streetinsider.com/dr/news.php?id=20412907","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2256914424","content_text":"After-Hours Stock Movers:Global Blood Therapeutics (NASDAQ: GBT) 30% HIGHER; said to draw takeover interest - BloombergYellow Corporation (NASDAQ: YELL) 27% HIGHER; reported Q2 EPS of $1.17, $0.72 better than the analyst estimate of $0.45. Revenue for the quarter came in at $1.42 billion versus the consensus estimate of $1.4 billion.Lucid Group (NASDAQ: LCID) 12% LOWER; reported Q2 EPS of ($0.33), $0.06 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $97.3 million versus the consensus estimate of $145.49 million.MercadoLibre (NASDAQ: MELI) 12% HIGHER; reported Q2 EPS of $2.43, $0.50 better than the analyst estimate of $1.93. Revenue for the quarter came in at $2.6 billion versus the consensus estimate of $2.51 billion.Skillz (NYSE: SKLZ) 12% LOWER; reported Q2 EPS of ($0.15), in-line with the analyst estimate of ($0.15). Revenue for the quarter came in at $93 million versus the consensus estimate of $92.8 million. Skillz sees FY2022 EPS of $275.00, versus the consensus of $399.13.Medifast (NYSE: MED) 11% LOWER; reported Q2 EPS of $3.87, $0.64 better than the analyst estimate of $3.23. Revenue for the quarter came in at $453.3 million versus the consensus estimate of $447.87 million. Medifast sees FY2022 EPS of $12.70-$14.10, versus the consensus of $15.38. Medifast sees FY2022 revenue of $1.58-1.66 billion, versus the consensus of $1.8 billion.Fortinet (NASDAQ: FTNT) 9% LOWER; reported Q2 EPS of $0.24, $0.02 better than the analyst estimate of $0.22. Revenue for the quarter came in at $1.03 billion versus the consensus estimate of $1.03 billion. Fortinet sees Q3 2022 EPS of $0.26-$0.28, versus the consensus of $0.27. Fortinet sees Q3 2022 revenue of $1.105-1.135 billion, versus the consensus of $1.12 billion. Fortinet sees FY2022 EPS of $1.01-$1.06, versus the consensus of $1.03. Fortinet sees FY2022 revenue of $4.35-4.4 billion, versus the consensus of $4.38 billion.PacBio (NASDAQ: PACB) 8% LOWER; Q2 Revenue of $35.5 million, a 16% increase compared with $30.6 million in the prior year period.Clorox (NYSE: CLX) 6% LOWER; reported Q4 EPS of $0.93, in-line with the analyst estimate of $0.93. Revenue for the quarter came in at $1.8 billion versus the consensus estimate of $1.86 billion. Clorox sees FY2023 EPS of $3.82-$4.22, versus the consensus of $5.26.Lumen Technologies (NYSE: LUMN) 6% LOWER; reported Q2 EPS of $0.35, $0.11 worse than the analyst estimate of $0.46. Revenue for the quarter came in at $4.61 billion versus the consensus estimate of $4.58 billion. The company reiterated its full-year 2022 financial outlookAlbemarle (NYSE: ALB) 5% HIGHER; reported Q2 EPS of $3.45, $0.45 better than the analyst estimate of $3.00. Revenue for the quarter came in at $1.48 billion versus the consensus estimate of $1.43 billion. Albemarle sees FY2022 EPS of $19.25-$22.25, versus the consensus of $15.87. Albemarle sees FY2022 revenue of $7.1-7.5 billion, versus the consensus of $6.89 billion.Sunrun (NASDAQ: RUN) 5% HIGHER; reported Q2 EPS of ($0.06), $0.07 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $584.6 million versus the consensus estimate of $501.53 million.Qorvo (NASDAQ: QRVO) 4% LOWER; reported Q1 EPS of $2.25, $0.14 better than the analyst estimate of $2.11. Revenue for the quarter came in at $1.04 billion versus the consensus estimate of $1.02 billion. Qorvo sees Q2 2023 EPS of $2.45-$2.65, versus the consensus of $2.64. Qorvo sees Q2 2023 revenue of $1.12-1.15 billion, versus the consensus of $1.14 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":103234140,"gmtCreate":1659583465867,"gmtModify":1663255519144,"authorId":3584006131453100,"author":{"id":3584006131453100,"idStr":"3584006131453100","authorId":3584006131453100,"name":"74rk","avatar":"https://static.tigerbbs.com/5d2cbf8ec63fa4fc1ffb7189ba15e1bc","vip":1,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9906433099,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":303,"commentSize":19,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2256914424"}